Further, ERK1/2 predicts poor prognosis in BlCa, so the ERK1/2 inhibitor ulixertinib—which has shown promise in clinical trials in patients with advanced gastrointestinal malignancies—may also prove to be an effective therapeutic approach for BlCa [210,211]. Here, MAPK3 is linked to bladder transitional cell carcinoma.